Where research peptides are made, and what USA-made means

Most research peptides are synthesized by contract manufacturers, many of them in China, some in Europe and the United States. What each step of the chain is, what a 'USA-made' label can legally mean, and what a chain-of-custody record should contain.

By Touchstone PeptidesSeptember 22, 20266 minute read

Most research peptides are made by contract synthesis houses. Many of the vials sold online trace to manufacturers in China, others to contract manufacturers in Europe and the United States. A peptide passes through at least five hands between the first amino acid and the label, and "made in" can honestly refer to any of them, so only a record that names each step shows where a vial came from.

How a research peptide is actually made

The chain is the same for a research vial and a pharmaceutical batch; what differs is the standard each step is run to and the paperwork that follows it.

Synthesis. The chain is assembled on a resin by solid-phase peptide synthesis, one protected amino acid at a time, then cleaved from the resin. The chemistry and its cost are described in solid-phase synthesis and the price.
Purification. The crude product is run through preparative reversed-phase HPLC, which is where the purity figure on a certificate is earned and where the trifluoroacetate counter-ion is picked up.
Lyophilization. The purified solution is freeze-dried to a bulk powder.
Fill and finish. Bulk powder is dissolved, dispensed by volume into vials, and lyophilized again, or dispensed as powder. This is the step that decides the milligrams in each vial, and it can happen at a different site, in a different country, from steps 1 to 3.
Labelling and distribution. A label is applied, a lot number assigned or inherited, and the vial moves through a distributor, a reseller, or both.

A "manufacturer" can mean the firm that ran step 1, the firm that ran step 4, or the firm whose name is on the label at step 5. Provenance is the record of which firm did which.

Who does the manufacturing

Peptide synthesis at scale is a contract business. The large contract development and manufacturing organizations describe themselves that way: PolyPeptide states that it "runs a global network of six GMP-certified facilities in Europe, the U.S. and India," and Bachem lists sites at Bubendorf, Vionnaz and Sisslerfeld in Switzerland, Torrance and Vista in California, and St. Helens in the United Kingdom. These firms make active ingredients for approved drugs under CGMP and, in some cases, research-grade material under lighter controls.

The research-peptide market mostly draws on a different tier: synthesis houses, many in China, that sell peptides by the gram to distributors and resellers who vial or relabel them. FDA's Import Alert 66-41 Red List carries entries for firms whose peptide shipments were detained, including a Zhengzhou chemical company whose shipment, manifested as aspartic acid, "was found to contain undeclared Ipamorelin." In March 2026, U.S. Customs and Border Protection in Cincinnati reported a shipper in China sending peptide vials that were already "prelabeled" for the US market before they left the factory; that case, and how detention works, is in Import Alert 66-41.

What "USA-made" can legally mean

The Federal Trade Commission's standard for an unqualified "Made in USA" claim is that the product be "all or virtually all" made in the United States, meaning "the final assembly or processing of the product occurs in the United States, all significant processing that goes into the product occurs in the United States, and all or virtually all ingredients or components of the product are made and sourced in the United States." The FTC's Made in USA Labeling Rule, 16 CFR Part 323, finalized in August 2021, applies that standard to labels and to online marketing and carries civil penalties.

Applied to the five steps above, an unqualified "USA-made" peptide would need the synthesis, the purification, the lyophilization and the fill to have happened in the United States, with the amino acids and resins also US-sourced or negligible. That is rare in the research tier. What is common is one of these, each of which is a different, and weaker, claim:

Synthesized in the USA. Steps 1 to 3 domestic. This is the strongest version short of the full standard and the least common.
Lyophilized or vialed in the USA. Bulk powder imported, step 4 domestic. The molecule was made elsewhere.
Tested in the USA. Nothing about manufacture at all; a domestic laboratory analysed an imported lot.
Labelled, packed or shipped from the USA. A relabelled import. Under the FTC standard this cannot carry "Made in USA," and a qualified claim such as "packaged in the USA" must not imply more.

None of these is dishonest if it is stated as what it is. The problem is the unqualified flag. A seller who will not say which of the four applies is, in effect, asking the buyer not to ask. The rest of the document checklist is in how to vet a peptide vendor.

What registration and a Drug Master File do and do not prove

Two FDA records get quoted as if they were quality marks, and neither is.

Drug establishment registration under section 510 of the FD&C Act and 21 CFR Part 207 is a listing requirement: manufacturers "are required to register their establishments with FDA" and to list the drugs they make for commercial distribution. FDA's own page states that "registering an establishment and listing drugs with FDA does not indicate the products are approved or that FDA has verified the information provided." A registration number tells you a firm has told FDA it exists. For a 503A pharmacy, a registered source is a statutory minimum for a bulk substance (21 U.S.C. 353a(b)(1)(A)(ii)); it is not a grade.

A Drug Master File is a confidential submission "used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products." A Type II DMF covers a drug substance. FDA's page is explicit that DMFs "are neither approved nor disapproved"; FDA reads them only when an application references them. A manufacturer that holds a DMF for a peptide has filed a process description with FDA. That is meaningful for a pharmaceutical buyer and says nothing about the research-grade lot in a reseller's vial, which was not made under it.

What a chain-of-custody record contains

A chain-of-custody record answers, for one lot, who had the material and what they did to it. The statutory minimum a pharmacy may accept, a registered source plus "valid certificates of analysis for each bulk drug substance," is a useful benchmark for anyone. A complete record for a research lot has these parts:

The synthesizing manufacturer, named, with the site that ran the synthesis and purification.
The manufacturer's certificate of analysis for the bulk lot, with its own lot number, method, date and signatory.
The fill record, if filling happened elsewhere: who dispensed the bulk into vials, on what date, and whether the vial lot number is the bulk lot number or a new one mapped to it. Why the number matters is in what a lot number is for.
The independent assay, drawn from the vialed lot by someone other than the manufacturer, with the same lot number on the report.
The reseller's statement of which of the above it did itself and which it bought in.

A record with a gap cannot tie the vial to the certificate. The commonest gap is the fill: a genuine manufacturer certificate for a bulk lot, attached to vials that were dispensed by an unnamed third party, with no statement of whether the powder in the vial is the powder the certificate describes.

This site names the manufacturer of each lot it sells, publishes a second, independent assay under the same lot number and makes no "USA-made" claim; the practice is at provenance and the reasoning in why a second laboratory.

Sources

For laboratory research use only. Not a drug, not a supplement, and nothing here is a claim about what any of this material does in a person or an animal.

Two things before you come in.